InnoCare Pharma Limited is a commercial-stage biopharmaceutical company focused on the discovery, development, and commercialization of drugs for the treatment of cancer and autoimmune diseases. The company operates a biopharmaceutical platform with in-house research and development capabilities, targeting both novel and evidence-based biological pathways. Its drug portfolio includes three launched products, with ongoing clinical trials and registration filings for Orelabrutinib in China and the U.S. The company also develops other clinical-stage candidates, including the TL1A/IL-23p19 bispecific antibody ICP-B161 and the combination of Metoclopramide and Orelabrutinib for marginal zone lymphoma. InnoCare Pharma serves patients in China and the U.S., with a focus on unmet clinical needs in hematological malignancies, solid tumors, and autoimmune conditions.

Summarised from the company's own disclosures, fiscal year ended Apr 2026

Industry Biotechnology Homepage innocarepharma.com
Sector Healthcare IR page innocarepharma.com/investor/esg
Tags
oncology, autoimmune diseases, bispecific antibodies, hematological malignancies, solid tumors, drug discovery, clinical development, commercialization, Orelabrutinib, ICP-B161, Metoclopramide
Press page innocarepharma.com/investor/news

Metrics

Valuation  
Market cap HK$ 18.6B
Market cap (USD) $ 2.37B
P/E 24.75
PEG —
P/BV 1.99
P/S 5.68
P/OCF 69.56
P/FCF —
Dividend yield —
Turnover / mcap 0.18%
Returns  
ROE 8.9%
ROI 8.0%
ROIC 8.0%
Profit margin 27.1%
Growth  
Revenue growing Yes
Profits growing Yes
Revenue up 3y Yes
Revenue up 5y No
Earnings growth 3y (net profit CAGR) —
Quality  
Profitable Yes
Margin expanding Yes
Buying back stock No
Diluting (TTM) Yes
Debt/Equity 11.6%
Podcast bulls (TTM) Sign up
Podcast bears (TTM) Sign up
Podcast sentiment (TTM) Sign up
Podcast sentiment % (TTM) Sign up
News sentiment (TTM) 112
Quality score 29.4%
Insiders  
Buys, 1w Sign up
Buys, 1m Sign up
Buys, 1y Sign up
Sells, 1w Sign up
Sells, 1m Sign up
Sells, 1y Sign up

Sign up to see this company's insider trades

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Revenue 2.375B 1.009B 738.537M 625.404M 1.043B 1.364M 1.247M 1.617M
Net profit 642.467M -440.633M -631.263M -886.593M -64.545M -463.793M -2.141B -549.95M

Figure FY 2025 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 FY 2019 FY 2018
Share price 14.99 4.14 — 10.45 20.5 12.9 — —
Price performance 12m 2.7 — — -0.51 0.71 — — —

Sign up to see institutional holdings

Sign Up

Podcast Mentions

Sign up to see podcast mentions and sentiment

Sign Up

Prompts

Innocare Pharma Limited (ticker 9969), listed in Hong Kong.

ETFs Holding Innocare Pharma Limited

ETF Weight in ETF Shares Market value As of
DFEM 0.01% 714,000 $ 1.084M Nov 12, 2026
DFAE 0.01% 319,000 $ 484.316K Nov 12, 2026
DFAX 0.00% 166,000 $ 252.027K Nov 12, 2026